Paradigm Capital Management Inc. NY bought a new stake in Revvity Inc. (NYSE:RVTY - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 107,850 shares of the company's stock, valued at approximately $11,999,000. Paradigm Capital Management Inc. NY owned approximately 0.10% of Revvity as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Ascentis Independent Advisors acquired a new position in shares of Revvity during the 1st quarter valued at about $29,000. CYBER HORNET ETFs LLC purchased a new stake in shares of Revvity in the second quarter valued at about $32,000. MUFG Securities EMEA plc acquired a new stake in Revvity during the second quarter worth about $34,000. SJS Investment Consulting Inc. increased its position in Revvity by 5,210.0% during the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company's stock worth $47,000 after purchasing an additional 521 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new position in Revvity during the second quarter worth about $49,000. 86.65% of the stock is owned by institutional investors and hedge funds.
Revvity Stock Performance
NYSE:RVTY opened at $123.08 on Tuesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The stock has a market capitalization of $13.73 billion, a P/E ratio of 58.61, a PEG ratio of 2.27 and a beta of 1.07. The company has a 50 day moving average price of $111.90 and a 200 day moving average price of $100.48. Revvity Inc. has a fifty-two week low of $81.22 and a fifty-two week high of $124.97.
Revvity (NYSE:RVTY - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.21 by $0.20. The company had revenue of $729.69 million for the quarter, compared to analyst estimates of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The firm's quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts forecast that Revvity Inc. will post 5.36 EPS for the current year.
Revvity Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be paid a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. Revvity's payout ratio is presently 13.33%.
Analyst Ratings Changes
Several research firms have weighed in on RVTY. Weiss Ratings upgraded shares of Revvity from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, July 30th. Wolfe Research started coverage on shares of Revvity in a report on Tuesday, June 2nd. They set a "peer perform" rating for the company. Barclays lifted their price target on shares of Revvity from $95.00 to $105.00 and gave the company an "equal weight" rating in a research report on Thursday, May 7th. JPMorgan Chase & Co. decreased their price objective on Revvity from $96.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday, May 6th. Finally, Sanford C. Bernstein assumed coverage on Revvity in a research report on Friday, June 26th. They issued a "market perform" rating and a $115.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $108.36.
Check Out Our Latest Stock Analysis on RVTY
About Revvity
(
Free Report)
Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.
Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Revvity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.
While Revvity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
